BGI Genomics Co Ltd (300676) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BGI Genomics Co Ltd (300676) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-3.08 Million ≈ $-451.41K USD) by net assets (CN¥9.37 Billion ≈ $1.37 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300676 net asset quality index to measure how much of total assets are equity-financed.
BGI Genomics Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how BGI Genomics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of BGI Genomics Co Ltd to evaluate the quality of earnings relative to operating cash generation.
BGI Genomics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BGI Genomics Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amot Investments Ltd
TA:AMOT
|
0.024x |
|
BREVILLE GROUP LTD
F:HDE
|
N/A |
|
Guangshen Railway Co Ltd
SHG:601333
|
0.009x |
|
Gudang Garam Tbk
JK:GGRM
|
0.037x |
|
Trump Media & Technology Group Corp.
NASDAQ:DJT
|
0.014x |
|
Santos Brasil Participações S.A
SA:STBP3
|
0.495x |
|
OneStream, Inc. Class A Common Stock
NASDAQ:OS
|
0.009x |
|
Eternal Materials Co Ltd
TW:1717
|
0.042x |
Annual Cash Flow Conversion Efficiency for BGI Genomics Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of BGI Genomics Co Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see BGI Genomics Co Ltd (300676) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.61 Billion ≈ $1.26 Billion |
CN¥-63.21 Million ≈ $-9.25 Million |
-0.007x | -171.13% |
| 2024-12-31 | CN¥9.27 Billion ≈ $1.36 Billion |
CN¥95.72 Million ≈ $14.01 Million |
0.010x | -74.73% |
| 2023-12-31 | CN¥10.00 Billion ≈ $1.46 Billion |
CN¥408.77 Million ≈ $59.82 Million |
0.041x | +219.10% |
| 2022-12-31 | CN¥10.22 Billion ≈ $1.50 Billion |
CN¥130.88 Million ≈ $19.15 Million |
0.013x | -95.12% |
| 2021-12-31 | CN¥9.44 Billion ≈ $1.38 Billion |
CN¥2.48 Billion ≈ $362.34 Million |
0.262x | -56.13% |
| 2020-12-31 | CN¥6.03 Billion ≈ $881.76 Million |
CN¥3.60 Billion ≈ $527.19 Million |
0.598x | +1088.56% |
| 2019-12-31 | CN¥4.46 Billion ≈ $652.35 Million |
CN¥224.25 Million ≈ $32.82 Million |
0.050x | +1315.25% |
| 2018-12-31 | CN¥4.13 Billion ≈ $604.67 Million |
CN¥14.69 Million ≈ $2.15 Million |
0.004x | -93.79% |
| 2017-12-31 | CN¥4.26 Billion ≈ $623.07 Million |
CN¥243.66 Million ≈ $35.66 Million |
0.057x | -15.59% |
| 2016-12-31 | CN¥3.45 Billion ≈ $505.22 Million |
CN¥234.07 Million ≈ $34.25 Million |
0.068x | -34.62% |
| 2015-12-31 | CN¥3.17 Billion ≈ $463.80 Million |
CN¥328.68 Million ≈ $48.10 Million |
0.104x | +1961.44% |
| 2014-12-31 | CN¥1.47 Billion ≈ $214.45 Million |
CN¥-8.16 Million ≈ $-1.19 Million |
-0.006x | -109.08% |
| 2013-12-31 | CN¥597.94 Million ≈ $87.50 Million |
CN¥36.70 Million ≈ $5.37 Million |
0.061x | -87.27% |
| 2012-12-31 | CN¥150.37 Million ≈ $22.00 Million |
CN¥72.49 Million ≈ $10.61 Million |
0.482x | -- |
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exom… Read more